Janssen Forms Global Public Health Group To Deliver Its Medicines To Developing World
This article was originally published in PharmAsia News
Executive Summary
With the formation of the GPH group, Janssen joins GSK and Sanofi in putting corporate focus on developing and delivering affordable medicines for developing countries. But where GSK seeks to improve outcomes and turn a profit, for now Janssen’s first priority is human health.
You may also be interested in...
Corporate Responsibility With Teeth: GSK’s Developing Countries Unit
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.
J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.